Knowledge is power, and this information, true for many cancers, is valuable for everyone to know—either to have an awareness of their own bodies and the factors that they can control, or to create spaces for empathy with persons they might encounter with cancer.
Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States. Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma... […]
As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were... […]
Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president
Patrizia Cavazzoni will rejoin Pfizer Inc. as chief medical officer and executive vice president.
Jenny Chang, a cancer clinician-scientist, was named executive vice president, president and CEO, and chief academic officer of the Houston Methodist Academic Institute.
The University of Hawai‘i Cancer Center and the Queen’s Health Systems will jointly develop oncology clinic space at the UH Cancer Center’s facilities in Kaka‘ako.
To expand access to breast cancer screening for patients across Virginia, UVA Health is rolling out a new mobile mammography coach.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Melanoma Research Program to support innovative, high-impact melanoma research.
A new analysis by the International Agency for Research on Cancer and collaborators evaluates the latest and future global burden of female breast cancer in about 50 countries worldwide.
